Clinicopathological and Prognostic Significance of MUC-2, MUC-4 and MUC-5AC Expression in Japanese Gastric Carcinomas

  • Xiao, Li-Jun (Department of Biochemistry and Molecular Biology, Institute of Pathology and Pathophysiology, College of Basic Medicine, China Medical University) ;
  • Zhao, Shuang (Department of Biochemistry and Molecular Biology, Institute of Pathology and Pathophysiology, College of Basic Medicine, China Medical University) ;
  • Zhao, En-Hong (Department of Surgical Oncology, the First Affiliated Hospital of Chengde Medical College) ;
  • Zheng, Xin (Department of Biochemistry and Molecular Biology, Institute of Pathology and Pathophysiology, College of Basic Medicine, China Medical University) ;
  • Gou, Wen-Feng (Department of Biochemistry and Molecular Biology, Institute of Pathology and Pathophysiology, College of Basic Medicine, China Medical University) ;
  • Xing, Ya-Nan (Department of Surgical Oncology, The First Affiliated Hospital of China Medical University) ;
  • Takano, Yasuo (Clinical Research Institute, Kanagawa Cancer Center) ;
  • Zheng, Hua-Chuan (Department of Biochemistry and Molecular Biology, Institute of Pathology and Pathophysiology, College of Basic Medicine, China Medical University)
  • 발행 : 2012.12.31


Background: The mucin components of the gastric gel layer function as a protective and lubricating factor against luminal acid and proteolytic enzymes. Alteration of mucin expression in gastric preneoplastic and neoplastic lesions has suggested potential roles in neoplastic processes. This study aimed to assess the clinicopathological and prognostic significance of MUC-2, MUC-4 and MUC-5AC in Japanese gastric cancer. Methods: Expression of MUC-2, -4 and -5AC was evaluated on tissue microarrays of gastric carcinomas and adjacent non-cancerous mucosa specimens by immunohistochemistry and compared with clinicopathological parameters and survival time of the patients. Results: The three mucins were found to be expressed to a lesser extent in gastric carcinomas in comparison with non-cancerous mucosa (p<0.05). MUC-2 expression was negatively correlated with tumor size, depth of invasion, and TNM staging of gastric cancer (p<0.05), while that of MUC-5AC was negatively associated with the depth of invasion, venous invasion, lymph node metastasis and TNM staging (p<0.05), but positively with MUC-4 and MUC-2 expression (p<0.05). There was higher MUC-2 expression in intestinal- than diffuse-type carcinomas (p<0.05). Kaplan-Meier analysis indicated no relationship between expression of the three mucins and the cumulative survival rate of patients, even stratified according to the depth of invasion (p>0.05). Conclusion: Down-regulated expression of MUC-2, -4 and -5AC may be involved in pathogenesis, invasion, metastasis or differentiation of gastric carcinoma. Their altered expression might therefore be employed as an indicator of pathobiological behavior.


  1. Wang RQ, Fang DC (2003). Alterations of MUC1 and MUC3 expression in gastric carcinoma: relevance to patient clinicopathological features. J Clin Pathol, 56, 378-84.
  2. Yamazoe S, Tanaka H, Sawada T, et al (2010). RNA interference suppression of mucin 5AC (MUC5AC) reduces the adhesive and invasive capacity of human pancreatic cancer cells. J Exp Clin Cancer Res, 29, 53.
  3. Yeh CN, Pang ST, Wu RC, et al (2009). Prognostic value of MUC4 for mass-forming intrahepatic cholangiocarcinoma after hepatectomy. Oncol Rep, 21, 49-56.
  4. Zheng HC, Li XH, Hara T, et al (2008). Mixed-type gastric carcinomas exhibit more aggressive features and indicate the histogenesis of carcinomas.Virchows Arch, 452, 525-34.
  5. Zheng H, Takahashi H, Murai Y, et al (2007). Pathobiological characteristics of intestinal and diffuse-type gastric carcinoma in Japan: an immunostaining study on the tissue microarray. J Clin Pathol, 60, 273-7.
  6. Zheng H, Takahashi H, Nakajima T, et al (2006).MUC6 downregulation correlates with gastric carcinoma progression and a poor prognosis: an immunohistochemical study with tissue microarrays. J Cancer Res Clin Oncol, 132, 817-23.
  7. Zhu Y, Zhang JJ, Zhu R, et al (2011). The increase in the expression and hypomethylation of MUC4 gene with the progression of pancreatic ductal adenocarcinoma. Med Oncol, 28, S175-84.
  8. Mejias-Luque R, Peiro S, Vincent A, Van Seuningen I, de Bolos C (2008). IL-6 induces MUC4 expression through gp130/ STAT3 pathway in gastric cancer cell lines. Biochim Biophys Acta, 1783, 728-36.
  9. Mesquita P, Peixoto AJ, Seruca R, et al (2003). Role of sitespecific promoter hypomethylation in aberrant MUC2 mucin expression in mucinous gastric carcinomas. Cancer Lett, 189, 129-36.
  10. Paleri V, Pearson JP, Bulmer D, et al (2004). Expression of mucin gene products in laryngeal squamous cancer. Otolaryngol Head Neck Surg, 131, 84-8.
  11. Rakha EA, Boyce RW, Abd El-Rehim D, et al (2005). Expression of mucins (MUC1, MUC2, MUC3, MUC4, MUC5AC and MUC6) and their prognostic significance in human breast cancer. Mod Pathol, 18, 1295-304.
  12. Rivera F, Vega-Villegas ME, Lopez-Brea MF (2007). Chemotherapy of advanced gastric cancer. Cancer Treat Rev, 33, 315-24.
  13. Senapati S, Chaturvedi P, Sharma P, et al (2008).Deregulation of MUC4 in gastric adenocarcinoma: potential pathobiological implication in poorly differentiated non-signet ring cell type gastric cancer. Br J Cancer, 99, 949-56.
  14. Shemirani N, Osipov V, Kolker A, Khampang P, Kerschner JE (2011). Expression of mucin (MUC) genes in mucoepidermoid carcinoma. Laryngoscope, 121, 167-70.
  15. Shibahara H, Tamada S, Higashi M, et al (2004). MUC4 is a novel prognostic factor of intrahepatic cholangiocarcinomamass forming type. Hepatology, 39, 220-9.
  16. Slomiany BL, Slomiany A (2005).Up-regulation in endothelin-1 by Helicobacter pylori lipopolysaccharide interferes with gastric mucin synthesis via epidermal growth factor receptor transactivation. Scand J Gastroenterol, 40, 921-8.
  17. Slomiany B, Slomiany A (2003). Impedance of Helicobacter pylori lipopolysaccharide interference with gastric mucin synthesis by peroxisome proliferator-activated receptor gamma activation involves phosphatidylinositol 3-kinase/ ERK pathway. IUBMB Life, 55, 97-102.
  18. Sobin LH, Wittekind CH (2002). TNM Classification of malignant tumors, 6th edn. New Jersey: John Wiley & Sons, Hoboken.
  19. Takami S, Mizuno T, Oyanagi T, et al (2012). Glucocorticoids inhibit MUC5AC production induced by transforming growth factor-${\alpha}$ in human respiratory cells. Allergol Int, 61, 451-9.
  20. Tamura Y, Higashi M, Kitamoto S, et al (2012). MUC4 and MUC1 expression in adenocarcinoma of the stomach correlates with vessel invasion and lymph node metastasis: an immunohistochemical study of early gastric cancer. PLoS One, 7, e49251.
  21. Vincent A, Ducourouble MP, Van Seuningen I (2008). Epigenetic regulation of the human mucin gene MUC4 in epithelial cancer cell lines involves both DNA methylation and histone modifications mediated by DNA methyltransferases and histone deacetylases. FASEB J, 22, 3035-45.
  22. Wang JY, Chang CT, Hsieh JS, et al(2003) Role of MUC1 and MUC5AC expressions as prognostic indicators in gastric carcinomas. J Surg Oncol, 8, 253-60.
  23. Huang WB, Shi LH, Zhu XQ, et al (2002). Expression of mucin MUC1 and MUC2 in colorectal carcinoma and their clinical significance. Ai Zheng, 21, 1231-4.
  24. Ilhan O, Han U, Onal B, Celik SY (2010). Prognostic significance of MUC1, MUC2 and MUC5AC expressions in gastric carcinoma. Turk J Gastroenterol, 21, 345-52.
  25. Inoue M, Tsugane S (2005). Epidemiology of gastric cancer in Japan. Postgrad Med J, 81, 419-24.
  26. Jeong YH, Kim MC, Ahn EK, et al (2007). Rare exonic minisatellite alleles in MUC2 influence susceptibility to gastric carcinoma. PLoS One, 2, e1163.
  27. Jinfeng M, Kimura W, Hirai I, et al (2003). Expression of MUC5AC and MUC6 in invasive ductal carcinoma of the pancreas and relationship with prognosis. Int J Gastrointest Cancer, 34, 9-18.
  28. Jung HH, Lee JH, Kim YT, Lee SD, Park JH (2000). Expression of mucin genes in chronic ethmoiditis. Am J Rhinol, 14, 163-70.
  29. Kang H, Min BS, Lee KY, et al (2011). Loss of E-cadherin and MUC2 expressions correlated with poor survival in patients with stages II and III colorectal carcinoma. Ann Surg Oncol, 18, 711-9.
  30. Lee HK, Cho MS, Kim TH (2012). Prognostic significance of muc4 expression in gallbladder carcinoma. World J Surg Oncol in press.
  31. Kelley JR, Duggan JM (2003). Gastric cancer epidemiology and risk factors. J Clin Epidemiol, 56, 1-9.
  32. Kim H, Seo JH, Kim KH (2003). The effect of p38 mitogenactivated protein kinase on mucin gene expression and apoptosis in Helicobacter pylori-infected gastric epithelial cells. Ann N Y Acad Sci, 1010, 90-4.
  33. Kim SM, Oh SJ, Hur B (2012). Expression of MUC1 and MUC4 in gallbladder adenocarcinoma. Korean J Pathol, 46, 429-35.
  34. Kocer B, Soran A, Kiyak G, et al (2004). Prognostic significance of mucin expression in gastric carcinoma. Dig Dis Sci, 49, 954-64.
  35. Kumada T, Tsuneyama K, Hatta H, Ishizawa S, Takano Y (2004). Improved 1-h rapid immunostaining method using intermittent microwave irradiation: practicability based on 5 years application in Toyama Medical and Pharmaceutical University Hospital. Mod Pathol, 17, 1141-9.
  36. Levi E, Klimstra DS, Andea A, Basturk O, Adsay NV (2004). MUC1 and MUC2 in pancreatic neoplasia. J Clin Pathol, 57, 456-62.
  37. Li XH, Zheng HC, Wang ZG, et al (2008). The clinicopathological and prognostic significance of MUC-1 expression in Japanese gastric carcinomas: an immunohistochemical study of tissue microarrays. Anticancer Res, 28, 1061-7.
  38. McGuckin MA, Linden SK, Sutton P, Florin TH (2011). Mucin dynamics and enteric pathogens. Nat Rev Microbiol, 9, 265-78.
  39. Mejias-Luque R, Linden SK, Garrido M, et al (2010). Inflammation modulates the expression of the intestinal mucins MUC2 and MUC4 in gastric tumors.Oncogene, 29, 1753-62.
  40. Akyurek N, Akyol G, Dursun A, Yamac D, Gunel N (2002). Expression of MUC1 and MUC2 mucins in gastric carcinomas: their relationship with clinicopathologic parameters and prognosis. Pathol Res Pract, 198, 665-74.
  41. Bu XD, Li N, Tian XQ, et al (2010). Altered expression of MUC2 and MUC5AC in progression of colorectal carcinoma. World J Gastroenterol, 16, 4089-94.
  42. Byrd JC, Yunker CK, Xu QS, Sternberg LR, Bresalier RS (2000). Inhibition of gastric mucin synthesis by Helicobacter pylori. Gastroenterology, 118, 1072-9.
  43. Carraway KL, Theodoropoulos G, Kozloski GA, Carothers Carraway CA (2009). Muc4/MUC4 functions and regulation in cancer. Future Oncol, 5, 1631-40.
  44. Cozzi PJ, Wang J, Delprado W, et al (2005). MUC1, MUC2, MUC4, MUC5AC and MUC6 expression in the progression of prostate cancer. Clin Exp Metastasis, 22, 565-73.
  45. Durai Babu S, Jayanthi V, Niranjali D, Reis CA, Devaraj H (2006). Expression profile of mucins (MUC2, MUC5AC and MUC6) in Helicobacter pylori infected pre-neoplastic and neoplastic human gastric epithelium. Mol Cancer, 5, 10.
  46. Elzagheid A, Emaetig F, Buhmeida A, et al (2012). Loss of MUC2 expression predicts disease recurrence and poor outcome in colorectal carcinoma. Tumour Biol in press.
  47. Enss ML, Cornberg M, Wagner S, et al (2000). Proinflammatory cytokines trigger MUC gene expression and mucin release in the intestinal cancer cell line LS180. Inflamm Res, 49, 162-9.
  48. Feng H, Ghazizadeh M, Konishi H, Araki T (2002). Expression of MUC1 and MUC2 mucin gene products in human ovarian carcinomas. Jpn J Clin Oncol, 32, 525-9.
  49. Guillem P, Billeret V, Buisine MP, et al (2000). Mucin gene expression and cell differentiation in human normal, premalignant and malignant esophagus. Int J Cancer, 88, 856-61.<856::AID-IJC3>3.0.CO;2-D
  50. Hollingsworth MA, Swanson BJ (2004). Mucins in cancer: protection and control of the cell surface. Nat Rev Cancer, 4, 45-60.

피인용 문헌

  1. Bile acid induces MUC2 expression and inhibits tumor invasion in gastric carcinomas vol.141, pp.7, 2015,
  2. Prognostic Value of MUC2 Expression in Colorectal Cancer: A Systematic Review and Meta-Analysis vol.2018, pp.1687-630X, 2018,
  3. Clinicopathologic correlation with MUC expression in advanced gastric cancer vol.14, pp.2, 2018,